BiotechTube

ANX007

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy

Trial Timeline

Feb 26, 2021 → Sep 13, 2023

NCT ID
NCT04656561

About ANX007

ANX007 is a phase 2 stage product being developed by Annexon for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT04656561. Target conditions include Geographic Atrophy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04656561Phase 2Completed
NCT03488550Phase 1Completed

Competing Products

20 competing products in Geographic Atrophy

See all competitors
ProductCompanyStageHype Score
avacincaptad pegolAstellas PharmaPhase 3
77
Avacincaptad PegolAstellas PharmaPhase 2/3
65
avacincaptad pegolAstellas PharmaApproved
85
Avacincaptad pegol (ACP)Astellas PharmaPre-clinical
23
Avacincaptad Pegol + ShamAstellas PharmaPhase 3
77
ABBV-6628 + SYFOVREAbbViePhase 1/2
41
FWY003 + PlaceboNovartisPhase 2
52
CLG561 + LFG316 + Sham injectionNovartisPhase 2
52
LFG316 + Sham + LFG316 Lower doseNovartisPhase 2
52
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
RO7669330 + Syfovre™ + Izervay™RochePhase 1
33
RO7303359RochePhase 1
33
SAR446597 + Sham ComparatorSanofiPhase 1/2
40
PozelimabRegeneron PharmaceuticalsPhase 1
32
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)Ionis PharmaceuticalsPhase 2
49
Tinlarebant + PlaceboBelite BioPhase 3
74
PegcetacoplanApellis PharmaceuticalsPre-clinical
18
APL-2 + APL-2Apellis PharmaceuticalsPhase 3
72

Other Products from Annexon

ANX005 + PlaceboPhase 3
72
TanruprubartPhase 3
72
VonaprumentPhase 3
72
ANX005Phase 2
47
ANX005Phase 2
47